FundedIQ
Biotechnology

Araris Biotech: Funding, Investors & Team (Sep 2026)

Araris Biotech AG (Araris) is a biotechnology start-up company. Their aim is to deliver a breakthrough technology platform that enables the development of next-generation ADC-based safe and potent drugs for various diseases and ailments.They are committed to produce high quality ADCs that do not require any engineering (antibody and/or cell-line) for site-specific conjugation instead the antibodies can directly be taken 'off-the-shelf'. The site-specifically modified ADCs can thus be produced rapidly within a few days and quality control and analysis can be performed quickly with high confidence. Their ADC technology is backed by two patents.

www.ararisbiotech.com LinkedIn Zürich, Switzerland 11-50 employees
Total raised
$39.2M
Rounds
2
Latest
Series A
Oct 2022

Araris Biotech has raised $39.2M across 2 funding rounds on record, the most recent a Series A of $24.0M announced in Oct 2022.

That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Araris Biotech Company Profile and Key Stats

Total funding raised
$39.2M
across 2 rounds on record
Funding rounds on record
2
Latest funding round
Series A
$24.0M in Oct 2022
Employees
11-50
reported band
Headquarters
Zürich, Switzerland

Latest funding round on record: Oct 2022.

Araris Biotech Funding Rounds

Date
Round
Amount
Series A
$24.0M
Undisclosed round
$15.2M

Araris Biotech raised $15.2M in an undisclosed round announced in Oct 2020.

2 years later, a Series A of $24.0M was announced in Oct 2022.

Araris Biotech Founders and Leadership Team

Name
Role
Contact
Dragan Grabulovski
Founder
Locked
Philipp Spycher
CEO
Locked

Contact details for the Araris Biotech team: 2 of 2 have an email address on file.

Start 14-day free trial →

Araris Biotech Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,182
$8.0M
881
$3.8M
8,378
$15M

Araris Biotech's latest round of $24.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Araris Biotech in Biotechnology and Zürich

Companies Similar to Araris Biotech

Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…

Series A $40.0M

At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…

Pre-Seed $3.0M

compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…

Undisclosed round $1.2M

MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…

Undisclosed round $200M

Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…

Undisclosed round $490k

Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…

Pre-Seed $120k

Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…

Undisclosed round $1.1M

AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…

Undisclosed round $4.0M

AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…

Undisclosed round $1.2M

Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…

Undisclosed round $1.4M

MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…

Undisclosed round $10.2M

Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…

Seed $7.5M

Araris Biotech Funding FAQs

What does Araris Biotech do?

Araris Biotech AG (Araris) is a biotechnology start-up company. Their aim is to deliver a breakthrough technology platform that enables the development of next-generation ADC-based safe and potent drugs for various diseases and ailments.They are committed to produce high quality ADCs that do not require any engineering (antibody and/or cell-line) for site-specific conjugation instead the antibodies can directly be taken 'off-the-shelf'. The site-specifically modified ADCs can thus be produced rapidly within a few days and quality control and analysis can be performed quickly with high confidence. Their ADC technology is backed by two patents.

How much funding has Araris Biotech raised?

Araris Biotech has raised $39.2M across 2 rounds on record. The most recent is a Series A of $24.0M announced in Oct 2022.

When did Araris Biotech last raise funding?

Araris Biotech's most recent funding round on record is a Series A of $24.0M, announced in Oct 2022.

Who founded Araris Biotech?

FundedIQ lists Dragan Grabulovski (Founder) at Araris Biotech.

Who is the CEO of Araris Biotech?

Philipp Spycher is listed as CEO at Araris Biotech.

Where is Araris Biotech headquartered?

Araris Biotech is based in Zürich, Zurich, Switzerland.

How many employees does Araris Biotech have?

Araris Biotech is in the 11-50 employee band.

How does Araris Biotech's funding compare to other Biotechnology startups?

Araris Biotech's latest round of $24.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.

About FundedIQ's Araris Biotech Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Araris Biotech is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.

Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.